ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2023
Epigenetics of Inflammatory Bowel Diseases.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- The epidemiology of inflammatory bowel disease: exploring the impacts of environmental factors.The Korean journal of internal medicine · 2026Review
- Clinical Impact of Cytomegalovirus Infection in Patients with Inflammatory Bowel Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
- Implications of gut microbiota-mediated epigenetic modifications in intestinal diseases.Gut microbes · 2025Review
- Nrf2 as a Molecular Guardian of Redox Balance and Barrier Integrity in IBD.Antioxidants (Basel, Switzerland) · 2025Review
- Sea Buckthorn Fermented Milk withFoods (Basel, Switzerland) · 2025Article
- Role of gut microbiota in the development of metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease.World journal of gastroenterology · 2025Review
- Rare Side Effect Due to Vedolizumab in a Patient with Ulcerative Colitis: Catatonic Depression.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Pioglitazone mitigates acetic acid-induced colitis in rats via epigenetic-modulation and antioxidant mechanisms.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The Role of Vitamin D in Inflammatory Bowel Diseases: From Deficiency to Targeted Therapeutics and Precise Nutrition Strategies.Nutrients · 2025Review
- Etrasimod in Treatment of Ulcerative Colitis: A Comprehensive Review.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Review
- Non-coding RNAs as a Critical Player in the Regulation of Inflammasome in Inflammatory Bowel Diseases; Emphasize on lncRNAs.Cell biochemistry and biophysics · 2025Review
- Gasdermin D: A New Inflammatory Biomarker in Assessing Clinical Disease Activity in Crohn's Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Chronic Gastrointestinal Disorders and miRNA-Associated Disease: An Up-to-Date.International journal of molecular sciences · 2025Review
- Regulatory Role of IGF2BP2 in Intestinal Mucosal Barrier Dysfunction in Ulcerative Colitis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Assessment of Serum Dynamic Thiol/Disulfide Homeostasis and Oxidative/Nitrosative Stress in Patients with Crohn's Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.Biomedicines · 2024Review
- The role of long non-coding RNA in Crohn's disease.Heliyon · 2024Review
- Advancements in Targeted Therapies for the Management of Crohn's Disease: A Comprehensive Review.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases are multifactorial, chronic, continuous, relapsing, and immune-mediated diseases of the gastrointestinal tract. It has been believed that mechanisms underlying inflammatory bowel diseases include genetic predisposition, environmental factors, and altered immune response to the gut microbiome. The epigenetic modulation takes place via chromatin modifications, including phosphorylation, acetylation, methylation, sumoylation, and ubiquitination. The methylation levels of colonic tissue were found well correlated to blood samples in inflammatory bowel diseases. Moreover, the methylation level of specific genes was different between Crohn's disease and ulcerative colitis. It has been shown that the enzymes affecting histone modifications like histone deacetylases and histone acetyltransferases do not act solely on histones but also affect the acetylation of many proteins such as p53 and STAT3. It has been already shown that a nonselective histone deacetylase inhibitor, Vorinostat (SAHA), which is currently being used in several cancer treatments, showed anti-inflammatory activities in mouse models. Among epigenetic alterations, long non-coding RNAs and microRNAs play significant roles in T-cell maturation, differentiation, activation, and senility. The long non-coding RNA and microRNA expression profiles can perfectly separate inflammatory bowel disease patients from healthy controls and are remarked as biomarkers of inflammatory bowel diseases. Overall, many studies have shown that epigenetic inhibitors can target significant signal pathways in the pathogenesis of inflammatory bowel diseases, and the impact of epigenetic inhibitors is being studied in clinical trials. In conclusion, exploring more epigenetic pathways regarding inflammatory bowel disease pathogenesis will help us to discover therapeutic targets and new drugs and agents targeting miRNAs in inflammatory bowel diseases. In general, discovering epigenetic targets could improve the diagnosis and treatment of inflammatory bowel diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.